Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups
BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022, principal investigator Prof. Dr. Johan Bennett presented the recent findings and highlighted the low TLF rate and the low scaffold thrombosis rate of Magmaris® Resorbable Magnesium Scaffold (RMS).1